Misguided, Overstimulated, and Frustrated: Understanding the Landscape of the Modern Patient’s Immune System in a World of Biologics, Immunotherapy, and Cellular Engineering

1. Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, van Vollenhoven RF, Voskuyl AE, Teng YKO, van Leew B, Bertsias G, Jayne D, Boumpas DT. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924. Epub 2020 Mar 27. PMID: 32220834.

2. Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762. PMID: 37827694.

3. AJKD Atlas of Renal Pathology: Membranous Lupus Nephritis, ISN/RPS Class V Mark A. Lusco, MD,1 Agnes B. Fogo, MD,1 Behzad Najafian, MD,2 and Charles E. Alpers, M; Am J Kidney Disease 2017

4. AJKD Atlas of Renal Pathology: Membranous Nephropathy Agnes B. Fogo, MD,1 Mark A. Lusco, MD,1 Behzad Najafian, MD,2 and Charles E. Alpers, MD; Am J Kidney Disease 2015

5. Alsharhan L, Beck LH Jr. Membranous Nephropathy: Core Curriculum 2021. Am J Kidney Dis. 2021 Mar;77(3):440-453. doi: 10.1053/j.ajkd.2020.10.009. Epub 2021 Jan 21. PMID: 33487481.

6. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. N Engl J Med. 1979 Dec 13;301(24):1301-6. doi: 10.1056/NEJM197912133012401. PMID: 388220.
7.Claudio Ponticelli, M.D., Pietro Zucchelli, M.D., Enrico Imbasciati, M.D., Leonardo Cagnoli, M.D., Claudio Pozzi, M.D., Patrizia Passerini, M.D., Claudio Grassi, M.D., Donatella Limido, M.D., Sonia Pasquali, M.D., Tiziano Volpini, M.D., Mauro Sasdelli, M.D., and Francesco Locatelli, M.D. Controlled Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy. April 12, 1984 N Engl J Med 1984;310:946-950 DOI: 10.1056/NEJM198404123101503 VOL. 310 NO. 1

8. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998 Mar;9(3):444-50. doi: 10.1681/ASN.V93444. PMID: 9513907.
9- Rojas-Rivera JE, Ortiz A, Fervenza FC. Novel Treatments Paradigms: Membranous Nephropathy. Kidney Int Rep. 2023 Jan 2;8(3):419-431. doi: 10.1016/j.ekir.2022.12.011. PMID: 36938069; PMCID: PMC10014375.
10. Fervenza Fernando C. et. Al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy  
11. Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel PA, Mihout F, Dussol B, Matignon M, Mousson C, Simon T, Ronco P; GEMRITUX Study Group. Rituximab for Severe Membranous Nephopathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol. 2017 Jan;28(1):348-358. doi: 10.1681/ASN.2016040449. Epub 2016 Jun 27. PMID: 27352623; PMCID: PMC5198292.
12. Fernández-Juárez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontán F, Ávila A, Rabasco C, Cabello V, Varela A, Díez M, Martín-Reyes G, Diezhandino MG, Quintana LF, Agraz I, Gómez-Martino JR, Cao M, Rodríguez-Moreno A, Rivas B, Galeano C, Bonet J, Romera A, Shabaka A, Plaisier E, Espinosa M, Egido J, Segarra A, Lambeau G, Ronco P, Wetzels J, Praga M; STARMEN Investigators. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021 Apr;99(4):986-998. doi: 10.1016/j.kint.2020.10.014. Epub 2020 Nov 7. PMID: 33166580.

13. F. Reggiani et al. Goodpasture syndrome and anti-glomerular basement membrane disease

14. OUZOT M, POISSON J, FAGUER S et al.: Rituximab in anti-GBM disease: A retrospective study of 8 patients. J Autoimmun 2015; 60: 74-9.

15. Hengel FE, Dehde S, Lassé M, Zahner G, Seifert L, Schnarre A, Kretz O, Demir F, Pinnschmidt HO, Grahammer F, Lucas R, Mehner LM, Zimmermann T, Billing AM, Oh J, Mitrotti A, Pontrelli P, Debiec H, Dossier C, Colucci M, Emma F, Smoyer WE, Weins A, Schaefer F, Alachkar N, Diemert A, Hogan J, Hoxha E, Wiech T, Rinschen MM, Ronco P, Vivarelli M, Gesualdo L, Tomas NM, Huber TB; International Society of Glomerular Disease. Autoantibodies Targeting Nephrin in Podocytopathies. N Engl J Med. 2024 Aug 1;391(5):422-433. doi: 10.1056/NEJMoa2314471. Epub 2024 May 25. PMID: 38804512.

16. Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023 Jul;619(7971):707-715. doi: 10.1038/s41586-023-06243-w. Epub 2023 Jul 26. PMID: 37495877.

17. Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023 Jul;619(7971):707-715. doi: 10.1038/s41586-023-06243-w. Epub 2023 Jul 26. PMID: 37495877.

18. Chan KK, Bass AR. Autoimmune complications of immunotherapy: pathophysiology and management. BMJ. 2020 Apr 6;369:m736. doi: 10.1136/bmj.m736. PMID: 32253223.